Trichostatin A (TSA)

Catalog No.S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
USD 247 In stock
USD 447 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • Gck expression in WT primary hepatocytes transduced with FOXO1 and KR-FOXO1 adenoviruses in the presence or absence of trichostatinA (TSA).

    Cell, 2017, 171(4):824-835.e18. Trichostatin A (TSA) purchased from Selleck.

    Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

  • (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 NH3CNZpHfW6ldHnvckBCe3OjeR?= M13JTlAvP87:TR?= NWT3SIRWOjSq M2HZTYV1cGGwb3y= MVTlcohidmOnczDFUoFEKGGlZYT5cIF1cW:wIHHu[EBqdmO{ZXHz[ZMhTU6jQzDhZpVv\GGwY3WgbY4hfGinIITveIFtKGOnbHygcJl{[XSnIHHu[EBifCC2aHWgZ4VtdCC|dYLmZYNm NV\vNnpvOjV5OEewO|k>
TE13 NVPsWVFjTnWwY4Tpc44hSXO|YYm= MVmwMlPPxE1? M4TEVlI1cA>? NVu5fnZTfXBvcnXneYxifGW|IGLBV3NHPUFibHX2[Yw> NV7Y[|ZJOjV3N{m2OlU>
TE13 MoTnRZBweHSxc3nzJGF{e2G7 M{Dr[lAvO87:TR?= MlO5NlRp NV3lUXJmcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbh?= MnL0NlU2Pzl4NkW=
MEFs MmXkSpVv[3Srb36gRZN{[Xl? MnL4Oe69VQ>? M{jITFE3cA>? NWT3WJQ6cW6lcnXhd4V{KHSqZTDFVGVEKGG2dHHjbI1mdnRuIGTpdkBl\WyrdnXyfUBidmRidHjlJIVn\mmlaXXuZ5khd2ZicHXk[ZN1[WxiZn;ycYF1cW:w Mo\5NlU1QDJ4M{S=
SW480  NXLjb3hPTnWwY4Tpc44hSXO|YYm= MonmNE4y|ryP MXO0PIg> MnjDSG1UVw>? MVjy[ZZmenOnczDFUXQ> MoTFNlU1OzR7OUe=
PC3  MWnGeY5kfGmxbjDBd5NigQ>? NHLkVXcxNjIQvF2= MkPEOFhp M2rIOWROW09? M2fvSJJmfmW{c3XzJGVOXA>? MXmyOVQ{PDl7Nx?=
SW480  MoTCSpVv[3Srb36gRZN{[Xl? M1Hx[lAvOc7:TR?= MV[0PIg> MXPEUXNQ M1Lh[oF1fGWwdXH0[ZMhcW64YYPpc44h[W6mIH3p[5JifGmxbh?= MnPYNlU1OzR7OUe=
PC3  MYnGeY5kfGmxbjDBd5NigQ>? NFjTS|AxNjIQvF2= M1fuclQ5cA>? NXrud4NYTE2VTx?= NITF[o5ifHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36= NWDYe5dwOjV2M{S5PVc>
SW480  MX\GeY5kfGmxbjDBd5NigQ>? NILzdmkxNjIQvF2= NX\BeoJHPDiq M{LOc2ROW09? NYS4bFhKcW6mdXPld{BqdmO{ZXHz[UBw\iCKRFHDNUBidmRiSFTBR|Ihd25iU3z1[{Bo\W6nczDwdo9ud3Snch?= M3;uVVI2PDN2OUm3
PC3  MVHGeY5kfGmxbjDBd5NigQ>? NVX3c2FDOC5zzszN MWO0PIg> M3TnTGROW09? NF[2[plqdmS3Y3XzJIlv[3KnYYPlJI9nKEiGQVOxJIFv\CCKRFHDNkBwdiCVbIXnJIdmdmW|IIDyc41wfGW{ M{nVZ|I2PDN2OUm3
A431 NXj5dmFESXCxcITvd4l{KEG|c3H5 Mn25Nk8yOC93MD:xNFBvVQ>? NYjlNY02PDiq MoLuSG1UVw>? MoDabY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3Sq M3XHVVI2OzdzME[5
A431 MYPGeY5kfGmxbjDBd5NigQ>? MX[1NI5O Ml;pNk83NzF{L{K0bC=> NH\HRXhFVVOR NHXEeG5i[3SrdnH0[ZMheDJzIHHu[EBqdmirYnn0d{BCXEZ|IHX4dJJme3Orb36= MUCyOVM4OTB4OR?=
MDA-MB-231 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPsNE03ODCwTR?= MlP4NlRp Mk\0SG1UVw>? M4DD[mlEPTBib3[gNVAxdk1? M2f6e|I2OTl{N{Kx
MCF7 NVXW[lRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:wMVYxOG6P NEnPTZUzPGh? MkPoSG1UVw>? NVLJWYJ[UUN3MDDv[kA4PW6P NFzyN5ozPTF7MkeyNS=>
SKOV-3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVexMVEx|ryP MW[yOIg> M2TaNmROW09? MkPWTWM2OCCxZjC1MlbPxE1? M1zXeVI2OTZ7NEmx
A549 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTCOnREOS1zMN88US=> Ml7wNlRp MYHEUXNQ NEn6OI1KSzVyIH;mJFMvOs7:TR?= MkD2NlUyPjl2OUG=
SKOV-3 NIDq[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrpXJExNjFvMd88US=> M2nRUlQ5cA>? NYXzNll4TE2VTx?= M4rDbmlEPTBib3[gNE44|ryP NVjlToZLOjVzNkm0PVE>
A549 NHXaeYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3SSFQxNjFvMd88US=> MUK0PIg> MmPZSG1UVw>? MVjJR|UxKG:oIECuNljPxE1? MWGyOVE3QTR7MR?=
SKOV-3 MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV:wMlAyNTBwOd88US=> M1HvZlczcA>? NUL6epRGTE2VTx?= MVPJR|UxKG:oIECuN|LPxE1? NWqycoRXOjVzNkm0PVE>
A549 NEXtPYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33xV|AvODFvMD65{txO M1PK[FczcA>? MkPDSG1UVw>? NHPGVoFKSzVyIH;mJFAvODcQvF2= NX64U4RtOjVzNkm0PVE>
HeLa M1GxSGZ2dmO2aX;uJGF{e2G7 NYLoUIxlOjVybl2= M2K1[VE3cA>? NF\CSXNFVVOR M3rP[olv[3KnYYPld{BEYVBzQUGgcXJPSSCneIDy[ZN{cW:wwrC= M160ZVI2OTF4Nki4
CNE2 MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH20O3gyODBvNkCwcm0> M3OwWlI1NzR6L{eybC=> MYjpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Mn;rNlQ6Pjl7MEG=
PC3 NX;XRXltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\S[lBLOTByLUGwNFBvVQ>? NYXES3FUOjSq M1nBWWlEPTBib3[gN|Axdk1? NWrnR2pMOjR6NUS2OVg>
LNCaP NVTE[4dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nQNVExOC1zMECwcm0> NX\sNHdUOjSq NHjuPY1KSzVyIH;mJFMxOG6P MoPiNlQ5PTR4NUi=
HeLa  NVrDNohkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLoO5Uz|ryP MUK0PIg> NVzYOYRM\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIFjd3W2IEK1KS=> NVzyPJBbOjR6NE[xN|U>
HMEC-1  M3PyWGZ2dmO2aX;uJGF{e2G7 NInvW2M{ODCwTR?= NEH5[ZQzPGh? NEfjfmlqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZtMgWmVITlJ|wrDtVm5C NWDxWFdqOjR5MUC2N|E>
HeLa NHH2dVhHfW6ldHnvckBCe3OjeR?= M4qwOVFuVQ>? MYWwMlVp MWnhZo9tcXOqZYOgeIhmKHSxdHHsJGhFSUNiYXP0bZZqfHl? MVuyOFcxPzR5NB?=
ACP02 NHjNPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTrNlUxNzN3MD:1NFBvVQ>? MmnxNlRp NGXaSFhl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgc4Yh[XCycn;4bY1ifGWueTC3NOKhLSCjdDCyOVDDqG6P NXzPdJV1OjR4Nki1OFc>
ACP03 NWLMSYRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnyNlUxNzN3MD:1NFBvVQ>? MX2yOIg> NHfENGVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgc4Yh[XCycn;4bY1ifGWueTC3NOKhLSCjdDCyOVDDqG6P NVHwWHB2OjR4Nki1OFc>
U87 GBM NUHTNY9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrWWHUyODBxM{CwM|UxOCCwTR?= M{GyNFczKGh? NUPuOlltOTByJTDleIhidm:u NWfIfoZzemWmdXPld{Bu\WGwIHPlcIwhdnWvYnXyJIJ6KDNzLDC1OEwh[W6mIEW4xsAm NV:0cGsyOjR2NkS4OFE>
U87 GBM MYDGeY5kfGmxbjDBd5NigQ>? NGDQOW0yODBxNUCwJG5u MXG0PEBp MlPPNVAxLSCndHjhco9t NUH2XJQ3UW6mdXPld{BU\W6nc3PlcoNmNUyra3WgRYx1\XKjdHnvcpMhcW5iToXjcIVieiCPb4LwbI9td2e7 MUmyOFQ3PDh2MR?=
RPE MoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTlS3h1OC5{L{CuOE8xNjhxMTFOwG0> MnOzNlQwPDhxN{KgbC=> NVTCS|lSTE2VTx?= M{PzSYlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIJ6KGOnbHygZ5lkdGViYYLy[ZN1 MYSyOFQ2PjZyMh?=
HT29  M4TVe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPsNVgxKG6P M2ji[VczKGh? NHTST|JKSzVyIH;mJFE5OCCwTR?= NXjKN2VnOjR|NkiyOlU>
hMSCs MXnGeY5kfGmxbjDBd5NigQ>? M1OzbVYvOjVibl2= NYOyPXM1OjRiaB?= MlzjSG1UVw>? MVTzeIFjcWyrenXzJGhqe3SxbnWgRYNmfHmuYYTpc44h[W6mIITo[UBGgHC{ZYPzbY9vKG:oIGDseZJqeG:2ZX70JGdmdmW| NW\5PYpuOjR|MUKzOVY>
Huh7  M4XrVGZ2dmO2aX;uJGF{e2G7 MoPkNE4yNzBwNT:xMlAh|ryP MXSyOIg> Mn;6d5VxeHKnc4Pld{B[XEiGQ{Kg[4Vv\SCneIDy[ZN{cW:w M2XYflI1OjZ7Nkey
SKOV3 NYTUeXFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUToWmN4OC5yNT2yJO69VQ>? MY[xNE8zPC92ODDo NIDNUXBFVVOR M4P1Uo1m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NEHQOGszPDJ{M{iwNS=>
A2780 NX\z[nVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjFUno6OC5yNT2yJO69VQ>? M4rMclExNzJ2L{S4JIg> MnH6SG1UVw>? M2frc41m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MnXtNlQzOjN6MEG=
SRA01/04  NXzNd2h[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmP5NE4zKM7:TR?= MYe0PEBp M4PTZWROW09? M1nUbJN2eHC{ZYPz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHSqcn;1[4ghe3WycILld5NqdmdidHjlJHBKO0txQXv0MEBxOziPQWDLJIFv\CCHUluxM|Ihe2mpbnHsbY5oKHCjdHj3ZZl{ M3LZUFI1OTV5OEe4
HLEB3 M33yTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjoRmwxNjJizszN MYi0PEBp MkW1SG1UVw>? M{f2SZN2eHC{ZYPz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHSqcn;1[4ghe3WycILld5NqdmdidHjlJHBKO0txQXv0MEBxOziPQWDLJIFv\CCHUluxM|Ihe2mpbnHsbY5oKHCjdHj3ZZl{ NGPTVpkzPDF3N{i3PC=>
SRA01/04  M2[5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHPNE41NzBwODFOwG0> NXLwN4dqPDhiaB?= MYfEUXNQ M{WzbYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MlfvNlQyPTd6N{i=
HLEB3 M{TqZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7hNE41NzBwODFOwG0> NHWzcWQ1QCCq M3y3UmROW09? NIjtSXpqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MYSyOFE2Pzh5OB?=
HCT116 M3jqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHvNE4zKM7:TR?= NWHYc4hoOTJiaB?= NYnBNopl\W6qYX7j[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBz[WSrYYTpc44> NWnzcVQ1OjRzMkKyN|E>
CA46 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn6N{83NzF{L{K0M|Q5KG6P MV[0PEBp M3HKVolvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iYYSgNlQh[W6mIES4JI5OyqB? MnTNNlQxPjR7NUG=
PMNs Ml7WSpVv[3Srb36gRZN{[Xl? MmDmN|Ahdk1? NWX3SFRpPDhiaB?= MWrpcohq[mm2czDl[oZmem:leYTvd4l{NCCKRFHDJIFkfGm4aYT5JIFv\CCUYXOgZYN1cX[rdIm= MVKyN|k5QDZzNx?=
H1299 M3\z[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\PT3JmOcLizszNxsA> M{jrflI1NzR6L{eyJIg> NGXJN2dmfGijbn;s MULpcoNz\WG|ZYOgZ4VtdCCmZXH0bEBi\nSncjCyOIg> M1;zdlI{QTF4NkC5
A549 NGDhcWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXpNE4zPS9yLkWvNUDPxE1? M{jWbFI1NzR6L{eyJIg> M1v1R4V1cGGwb3y= NFfnZotqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ M2jrcVI{QDZ5OUmx
H1299 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrrNE4zPS9yLkWvNUDPxE1? Mmr6NlQwPDhxN{KgbC=> NHTLS21mfGijbn;s NF;4ZZRqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MV:yN|g3Pzl7MR?=
A549 NHr0TIFCeG:ydH;zbZMhSXO|YYm= M1rTe|AvPS9zIN88US=> MYS0PEBp NHLIb4xmfGijbn;s Mni4bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MnnjNlM5Pjd7OUG=
H1299 NXLnXFI{SXCxcITvd4l{KEG|c3H5 NXi5WVhJOC53L{Gg{txO NIrEepg1QCCq Ml;P[ZRp[W6xbB?= NWm1T2ZYcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MXuyN|g3Pzl7MR?=
SUM149PT NV74ZpltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrK[IwzNzdwNT:xNEDPxE1? MYC0PEBp MlX3SG1UVw>? NHjlPJJqdmS3Y3XzJINmdGxiZHXheIgh[XRiMjFOwG0hcW6|ZX7zbZRqfmWueR?= MVqyN|c6OjZ|OB?=
SUM190PT NHW5Z5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj3[po2OC9zMECvNlUxKG6P MU[0PEBp M2DNeGROW09? MWXpcoR2[2W|IHPlcIwh\GWjdHigZZQhPTBibl2gd4Vve2m2aY\lcJk> NIr0e4ozOzd7Mk[zPC=>
HCT1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XCOVAvOi9zLkCvOU4xKM7:TR?= MUSxNk8zPC9|Nj:0PEBp MUXpcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= M{e2T|I{PzdyMECw
Lovo NEnMVpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nlOlAvOi9zLkCvOU4xKM7:TR?= Mm\VNVIwOjRxM{[vOFghcA>? NGHBXmhqdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MnXBNlM4PzByMEC=
AGS NYnSO5JQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPBW24xNjBzNT2xJO69VQ>? MknsO|IhcA>? MWDpcoR2[2W|IHPlcIwh\GWjdHigZ49v[2WwdILheIlwdiCmZYDlcoRmdnSueR?= MmKyNlM4PDVyMkS=
Huh7 NX\PcWpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33uZVEh|ryP Mn3VNlQhcA>? M1WzcmROW09? NIe1dGZz\WS3Y3XzJIFjd3W2IEKwKUB3cWGkaXzpeJnDqA>? NGL3U3IzOzZ2M{mzNy=>
ECC1 MUTGeY5kfGmxbjDBd5NigQ>? NVfibIxTPTByIH7N MVS1JIQ> NH3IV|hFVVOR NHfpZm1qdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= M4PlcFI{PTNyN{[5
HEC1A M{nQXmZ2dmO2aX;uJGF{e2G7 NXPFbVRSPTByIH7N MoHGOUBl NXHFVlBWTE2VTx?= MojJbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? Mn7hNlM2OzB5Nkm=
EN1 NGrPXm5HfW6ldHnvckBCe3OjeR?= NEOxdXY2ODBibl2= NH3lZWM2KGR? MnL6SG1UVw>? Mn\rbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? M{KzWFI{PTNyN{[5
MFE296 M4\OVWZ2dmO2aX;uJGF{e2G7 M3PrV|UxOCCwTR?= NEO2UGM2KGR? MlTmSG1UVw>? MY\pcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? MYeyN|U{ODd4OR?=
HASMCs MmnYSpVv[3Srb36gRZN{[Xl? NX3nO45QOC13MECgcm0> MWq2JIQ> NWTqPG9L\G:5bj3y[Yd2dGG2ZYOgeIhmKGW6cILld5Nqd25ib3[gTGFFSyCjbnSgZ4VtdCC4aXHibYxqfHl? NYLWflFYOjN3MUi0Olc>
U373 M{jNc2Z2dmO2aX;uJGF{e2G7 M2nBN|AvOjVxMD61M|Eh|ryP MWWyOEBp M361OYlv[3KnYYPld{BRWi2EIHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOWF7[WSF NUjVT4Q1OjN2N{SxO|E>
ARN8  M1;WW2Z2dmO2aX;uJGF{e2G7 NHXMbpYxNjB3LUKg{txO MVeyOEBp NXHH[21remWmdXPld{B1cGViaX7keYN1cW:wIH;mJJA2Oy2mZYDlcoRmdnRiZ3Xu[ZMh[nliToX0cIlvNTN? NH;IdHEzOzR5MEW0NC=>
MCF7 NV\a[5g5TnWwY4Tpc44hSXO|YYm= MoXBNE4xPS1{IN88US=> NVLGVIhxOjRiaB?= NITaNnRz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gdFU{NWSncHXu[IVvfCCpZX7ld{BjgSCQdYTsbY4uOw>? M3HZUVI{PDdyNUSw
H1299  MVjGeY5kfGmxbjDBd5NigQ>? M2LTTVAvOzQkgKOxxsDDvU1? MXOyOE81QCCq MYPEUXNQ NX;yZ3ZrcW6lcnXhd4V{KEVvY3HkbIVzcW5icILveIVqdiCuZY\lcJMh\G:|ZTDk[ZBmdmSnboTsfS=> M{LFflI{PDZzOUe1
H1299 MkjSSpVv[3Srb36gRZN{[Xl? M2rXeVAvPSEQvF2= NX;tNHppPDhiaB?= M{H0bmROW09? MVLpcohq[mm2czD0bIUhdWmpcnH0c5J6KHCxdHXueIlidCClb33ibY5mKHerdHigd4ltcWKrbnnu NEjreHkzOzR4MUm3OS=>
H1299 MYLGeY5kfGmxbjDBd5NigQ>? M{jEW|AvPSEQvF2= M3vQTVQ5KGh? M1[z[2ROW09? MlnvbY5pcWKrdIOgeIhmKGmwdnHzbZZmdmW|c9MgJINwdWKrbnWge4l1cCC|aXzpZolvcW5? M3nWXlI{PDZzOUe1
MG-63  NH\jT4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkS5NE4{KM7:TR?= NFHXXWMyOi17NjDo MlLUSG1UVw>? NYjGN3JbcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> NXm0NndSOjN2NUG4NVc>
LM8 NHTWSm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\LNE4{KM7:TR?= NVX4bJFVOTJvOU[gbC=> NGPzOZhFVVOR M{nycolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDjc{11emWjdH3lcpQhf2m2aDDt[ZRnd3KvaX6= M2jnVVI{PDVzOEG3
K562 NXrpdoN{TnWwY4Tpc44hSXO|YYm= NFTpWmMxNjVizszN M3zUd|I1KGh? NV[0RnF7\XSqYX7vcC=> NUjScZFG\GWlcnXhd4V{KHSqZTDlcpp6dWViYXP0bZZqfHlib3[gTGRCS3NiY3:teJJm[XSvZX70JJdqfGhiY4XyZ5VucW5? NXTxS29EOjN2M{C5OVc>
HEL NEnOboFHfW6ldHnvckBCe3OjeR?= MYGwMlUh|ryP NXjpVoJrOjRiaB?= MXzleIhidm:u NVTSfHZv\GWlcnXhd4V{KHSqZTDlcpp6dWViYXP0bZZqfHlib3[gTGRCS3NiY3:teJJm[XSvZX70JJdqfGhiY4XyZ5VucW5? NFT5T|czOzR|MEm1Oy=>
HL60 NYSycVQ6SXCxcITvd4l{KEG|c3H5 M3;CN|Eh|ryP NFPENoszPCCq NG\QcIxqdmS3Y3XzxsBk\WyuIHTlZZRp MlPVNlM1ODB3MUm=
KG1 MorZRZBweHSxc3nzJGF{e2G7 MYexJO69VQ>? M33NZVI1KGh? NXnrc3Z4cW6mdXPld:Kh[2WubDDk[YF1cA>? NEP2S2MzOzRyMEWxPS=>
Kazumi NFrqRVNCeG:ydH;zbZMhSXO|YYm= Mn;wNUDPxE1? NVjPNY1EOjRiaB?= NWTRSJhwcW6mdXPld:Kh[2WubDDk[YF1cA>? NH3YXnUzOzRyMEWxPS=>
K562 NFXmc29CeG:ydH;zbZMhSXO|YYm= MorINUDPxE1? MWqyOEBp MVzpcoR2[2W|wrDj[YxtKGSnYYTo M1rSSFI{PDByNUG5
THP1 NIe4e3ZCeG:ydH;zbZMhSXO|YYm= MU[xJO69VQ>? NXfCNnFNOjRiaB?= MXLpcoR2[2W|wrDj[YxtKGSnYYTo MnPmNlM1ODB3MUm=
SH-SY5Y NGC0RXBHfW6ldHnvckBCe3OjeR?= MkG0NlUxKG6P MljFNVYhcA>? M2TtOoNp[W6pZYOg[ZhxemW|c3nvckBx[XS2ZYLuJI9nKGenbnXzJIlvfm:udnXkJIlvKGOqb3zld5Rmem:uIIP5cpRp\XOrczygeZB1[WunIHHu[EBm\m[udYi= NIT3V5EzOzN{NkSyNi=>
HEK293 NWWyd5JDTnWwY4Tpc44hSXO|YYm= NXv4dIJGOSEEtV5CpC=> NUGzOJhHOThiaNMg NFvhZo5qdmirYnn0d{B1cGVia3HsbZJqdi15LX3l[IlifGWmIILlZ5J2cXSvZX70JI9nKHO7boDobYxqdi1zIHHn[5Jm\2G2ZYOgbY51dyCjZ3fy[ZNwdWW| NFfI[VYzOzJ6NEi0PC=>
HTK NUPmNVNSTnWwY4Tpc44hSXO|YYm= M4T4c|QxOCCwTR?= NHnBOYQ4OiCq MYnpcohq[mm2czDUS2Yu|rMkgKPJcoR2[2WmIF35c4Zq[nKxYnzhd5QhTGmoZnXy[Y51cWG2aX;u MWCyN|I5PDByMh?=
HTK NFn1T3BHfW6ldHnvckBCe3OjeR?= MVSxNFAuQDBybl2= MXS3NkBp NHLMZXZjdG:la4OgWGdHNc7{4pETTY5lfWOnZDDSU3Mh[W6mIFiyU|LDqEGlY4XteYxifGmxbh?= MWmyN|I5PDByMh?=
Caco-2  NVzFO3JFTnWwY4Tpc44hSXO|YYm= M2LTeVEhyrWPwrC= NXj3cZhKOjRiaB?= NUnJVVZY\GWlcnXhd4V{KFOHUmSgdJJwfGWrbjDlfJBz\XO|aX;u M3q4eFI{OTl3MEew
HeLa NXPFWlVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnQNVAxKG6P M2Xte|I1KGh? NXSyTWRETE2VTx?= M4DnSmlEPTBib3[gNVAxdk1? NYe2cmFGOjNzNkW3OFg>
HeLa MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XzTlQxKG6P MoTSOFghcA>? MWfEUXNQ NUPiTFkxUUN3MDDv[kA1OG6P MlnPNlMyPjV5NEi=
HeLa MojrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjxS5N5OjBibl2= NF7TZlI4OiCq MnTjSG1UVw>? M{fwOGlEPTBib3[gNlBvVQ>? NHvLd|UzOzF4NUe0PC=>
HeLa NFrFboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{myTVExNzNyL{WwJI5O MlPvO|IhcA>? M{PpfWROW09? M4rN[4lv[3KnYYPld{B1cGViboXtZoVzKG:oIF3NVEAp|pUQqH2pJIxwe3NiY3XscJMh\G:|ZTDk[ZBmdmSnboTsfS=> M{jwNVI{OTZ3N{S4
MDA-MB-231 MmfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETCOmQzPS12MECgcm0> NXzBSW5kPDhiaB?= MmPlTWM2OCCxZjCyOlMvOm6PwrC= NXW4XYplOjNyNUWxPVg>
MCF-7  MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7GfmozPS12MECgcm0> NV71eI9QPDhiaB?= NYXYcWtzUUN3MDDv[kAzOjBwNH7N M17zOFI{ODV3MUm4
ECC-1  MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVGxNFAhdk1? NFHtOXYzPCCq MX;leIhidm:u M{jKRolv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN3JR?= MWCyN|AzQDhyMx?=
HEC-1A NELm[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XGSFExOCCwTR?= NGXmPWkzPCCq M1;jcoV1cGGwb3y= Mly3bY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzln NX7H[WpyOjNyMki4NFM>
NHAC-kn NWTYdXdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXDRnZwOTBxMUCwM|UxOCCwTR?= NYDlWI55OTJiaB?= Mo\WSG1UVw>? MUXJR|UxKG:oIEWwNI5O M{nJW|I{ODF5OEex
A549 Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjSNlUxKG6P NWLpdlY4Pi15MjDo NIC3[FBFVVOR NIrDNWpk[XW|ZYOgZUBoemWjdHXyJIlvcGmkaYTvdpkh\W[oZXP0JINwdWKrbnWge4l1cCCWWGSgc5Ih\XKub4Tpcolj MVeyNlk6PDd6MB?=
MG-63 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4G2XFMxOCCwTR?= M3\6RlEzKGh? MYPEUXNQ NUjHTlVKcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDh4JR?= MlHzNlI4QTl|M{i=
MG-63 NHPVSlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\1RlMxOCCwTR?= NV7JcWdWOjRiaB?= MVrEUXNQ M13k[4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A3PyV? NIC1[2kzOjd7OUOzPC=>
MG-63 NYX3WGNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DVSlMxOCCwTR?= NF7PWmY1QCCq M1\SVmROW09? MnrDbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFU3LQ>? NFPFe4czOjd7OUOzPC=>
HL60  NH\FNmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXOxOVAuOzVyIH7N MYqyOEBp MnTYbY5kemWjc3XzJINmdGxiYYDvdJRwe2m|wrD3bIVvKGOxbnPlcpRz[XSrb37zJIhq\2incjD0bIFvKDJ3MDDuUS=> MX:yNlc2Ozd|OR?=
U937 NVvwUnJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFz1NIQyPTBvM{WwJI5O M1TkcFI1KGh? NWjmTVZ7cW6lcnXhd4V{KGOnbHygZZBweHSxc3nzxsB4cGWwIHPvcoNmdnS{YYTpc45{KGirZ3jldkB1cGGwIEK1NEBvVQ>? M4PhfVIzPzV|N{O5
SCC-6 NEnPRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPPNlAxNTN{MECgcm0> MkLLNVIwOjRxNEigbC=> NH\qVFNFVVOR NXH1XldDcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hd2ZiU1PDMVYh[2WubIOgbY4h[SCmb4PlMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy MnPqNlI2PTJ|MkG=
U87  MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nNUlExOC1|MECgcoc> MkXMNlQhcA>? NYruepZzcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDd{JTCgZZQhOjBybne= MVSyNlI4ODh2OR?=
K562 MVXGeY5kfGmxbjDBd5NigQ>? M13IW|Eh|ryP MkTuNVIhcA>? Mo\nSG1UVw>? Mn;k[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK= MmjPNlIyPzlzOUi=
Reh NVPjdmlXTnWwY4Tpc44hSXO|YYm= MXqwMlMwOSEQvF2= M2XSdVEzKGh? Mn;BSG1UVw>? NXX2b3J1\W6qYX7j[ZMhfGinIHX4dJJme3Orb36gc4YhWlWQWEOgbY5lfWOnZDDifUA2NWG8YT3D[HI> MV[yNlE4QTF7OB?=

... Click to View More Cell Line Experimental Data

In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Formulation: Dissolved in DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02959905 Recruiting Metastatic Melanoma BGI, China|Sun Yat-sen University December 2016 Phase 1
NCT02486965 Recruiting Fibromyalgia University Hospital, Brest October 2015 --
NCT01954433 Recruiting Glenohumeral Arthritis and/or Rotator Cuff Tear Arthropathy (TSA)|Rotator Cuff Tear (RCR)|Trapeziometacarpal Osteoarthritis (TMC OA) Matthias Flury|Winterthur Institute of Health Economics (WIG), Switzerland|Schulthess Klinik November 2013 --
NCT01575106 Unknown status Pain Massachusetts General Hospital June 2012 --
NCT02762903 Completed Osteoarthritis Columbia University August 2009 --
NCT00914173 Completed Pain Medasense Biometrics Ltd November 2008 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • Answer:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID